Sildenafil For Meniere's Disease
A Multicentre, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study Of The Efficacy and Safety Of Sildenafil Given For The Acute Treatment Of Meniere's Disease
Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
A PHASE4 clinical study on Meniere's Disease, this trial is completed. The trial is conducted by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. and has accumulated 7 data snapshots since 2002. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Mar 2021 — Jul 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Mar 2021 [monthly]
Completed PHASE4
-
Oct 2018 — Jan 2021 [monthly]
Completed PHASE4
Phase: PHASE2 → PHASE4
▶ Show 2 earlier versions
-
Jun 2018 — Oct 2018 [monthly]
Completed PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE2
First recorded
Jun 2002
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
For direct contact, visit the study record on ClinicalTrials.gov .